Abstract
There is little doubt that biochemical investigation of human postmortem brain tissue has made a substantial contribution to the understanding and treatment of disease. It was as a direct result of the observation of a dopamine deficit in the corpus striatum of Parkinson’s disease patients that L-dopa was introduced and found to be so successful (Birkmayer and Hornykiewicz 1962). Unfortunately, such a valuable advance has yet to be made in other fields of neuropsychiatry, although recently some potentially important findings have been made towards our understanding of schizophrenia and the mechanisms of antipsychotic drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36: 927–934
Bird ED, Spokes EGS, Iversen LL (1979) Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102: 347–360
Birkmayer W, Horaykiewicz O (1962) Der L-3,4-Dioxyphenylalanin ( L-Dopa)-Effekt beim Parkinson-Syndrom des Menschen. Arch Psychiatr Nervenkr 203: 560–574
Borison RL, Fields JZ, Diamond RI (1981) Site specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacology 20: 1321–1322
Clow A, Theodorou A, Jenner P, Marsden CD (1980) Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur J Pharmacol 63: 135–144
Crow TJ, Owen F, Cross AJ, Ferner N, Johnstone EC, McCreadie RM, Owens DGC, Poulter M (1981) Neurotransmitter enzymes and receptors in post mortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors is associated with the type I syndrome. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, pp 85–96
Flor-Henry P (1969) Psychosis and temporal lobe epilepsy: a controlled investigation. Epilepsia 10: 363–395
Gruzelier JH (1981) Cerebral laterality and psychopathology: fact and fiction. Psychological Med 11: 219–227
Hornykiewicz O (1982) Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 299: 484–486
Mackay AVP, Bird ED, Spokes EL, Rossor M, Iversen LL, Creese I, Snyder SH (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet 11: 223–225
Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997
Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 11: 915–916
Peroutka SJ, Lebowitz RM, Snyder SH (1981) Two distinct serotonin receptors with different physiological functions. Science 212: 827–829
Reynolds GP (1983a) (3H)-Ketanserin binding to 5-HT2 receptors in human brain. Br J Pharmacol 78:273 p
Reynolds GP (1983b) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527–529
Reynolds GP, Riederer P, Jellinger K, Gabriel E (1981) Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 20: 1319–1320
Reynolds GP, Cowey L, Rossor M, Iversen LL (1982a) Thioridazine is not specific for limbic dopamine receptors. Lancet 11: 499–500
Reynolds GP, Riederer P, Jellinger K, Gabriel E (1982b) Effects of neuroleptic treatment and disease state on dopamine receptors in post-mortem schizophrenic brain. Neuroscience 7: S177
Reynolds GP, Rossor MN, Iversen LL (1983) Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Trans [Suppl] 18: 273–277
Snyder S, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61
Stevens JR (1979) Schizophrenia and dopamine regulation in the mesolimbic system. Trends Neurosci 2: 102–105
Trulson ME, Jacobs BL (1979) Long-term amphetamine treatment decreases brain serotonin metabolism: implications for theories of schizophrenia. Science 205: 1295–1297
Whitaker PM, Crow TJ, Ferrier IN (1981) Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 38: 278–280
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Reynolds, G.P. (1985). Receptors, Neuroleptics and Dopamine Concentrations in Schizophrenia — Postmortem Studies of Human Brain Tissue. In: Beckmann, H., Riederer, P. (eds) Pathochemical Markers in Major Psychoses. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69743-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-69743-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69745-6
Online ISBN: 978-3-642-69743-2
eBook Packages: Springer Book Archive